Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now

Core Insights - Summit Therapeutics has transitioned from a small-cap biotech to a large-cap valuation, primarily due to regulatory advancements for its leading candidate, ivonescimab, which is already approved in China and has the potential to compete with Keytruda [1] - The company faces significant near-term uncertainty, particularly regarding the FDA's decision on ivonescimab, which is expected by November 14 [4] - Smaller biotech firms like Axsome Therapeutics and Madrigal Pharmaceuticals are also making progress and could potentially surpass Summit by the end of 2026 [1] Company Developments - Summit Therapeutics has submitted an application to the FDA for ivonescimab in combination with chemotherapy for treating EGFR-mutated non-small cell lung cancer, based on a global study with 38% of participants from Western countries [2] - Despite strong results, ivonescimab has not shown a statistically significant improvement in overall survival among non-Chinese patients, which is a critical requirement for FDA approval [3][4] - The FDA has indicated that a statistically significant overall survival benefit is necessary for marketing authorization, raising concerns about the likelihood of approval [4] Market Context - Axsome Therapeutics has a market cap of $8.1 billion, while Madrigal Pharmaceuticals is valued at $10.2 billion, making Summit's valuation approximately 48% higher than Axsome's [5] - In the biotech industry, a significant clinical setback could lead to a drop of 20% or more in stock prices, highlighting the volatility and risks associated with such investments [5]